Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement
- PMID: 34364544
- DOI: 10.1016/S2468-1253(21)00183-7
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement
Abstract
The term non-alcoholic fatty liver disease (NAFLD), and its definition, have limitations for both adults and children. The definition is most problematic for children, for whom alcohol consumption is usually not a concern. This problematic definition has prompted a consensus to rename and redefine adult NAFLD associated with metabolic dysregulation to metabolic (dysfunction)-associated fatty liver disease (MAFLD). Similarities, distinctions, and differences exist in the causes, natural history, and prognosis of fatty liver diseases in children compared with adults. In this Viewpoint we, an international panel, propose an overarching framework for paediatric fatty liver diseases and an age-appropriate MAFLD definition based on sex and age percentiles. The framework recognises the possibility of other coexisting systemic fatty liver diseases in children. The new MAFLD diagnostic criteria provide paediatricians with a conceptual scaffold for disease diagnosis, risk stratification, and improved clinical and multidisciplinary care, and they align with a definition that is valid across the lifespan.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests JG reports personal fees from Gilead, Pfizer, AstraZeneca, Pharmaxis, Cincera, Novartis, Roche, Intercept, Novo, and MSD during the writing of the report. LAB reports personal fees from Novo Nordisk. CM reports personal fees from Evira and Itrim, and grants and personal fees from Novo Nordisk. ME reports personal fees from Pfizer. The other authors declare no competing interests.
Comment in
-
Metabolic dysfunction-associated fatty liver disease and insulin resistance in type 1 diabetes.Lancet Gastroenterol Hepatol. 2021 Dec;6(12):985-986. doi: 10.1016/S2468-1253(21)00343-5. Lancet Gastroenterol Hepatol. 2021. PMID: 34774157 No abstract available.
-
Metabolic-associated fatty liver disease in children and adolescents: Mexican experience.Lancet Gastroenterol Hepatol. 2021 Dec;6(12):986. doi: 10.1016/S2468-1253(21)00391-5. Lancet Gastroenterol Hepatol. 2021. PMID: 34774158 No abstract available.
-
Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition.Hepatobiliary Surg Nutr. 2023 Aug 1;12(4):611-615. doi: 10.21037/hbsn-23-308. Epub 2023 Jul 11. Hepatobiliary Surg Nutr. 2023. PMID: 37600999 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
